Page last updated: 2024-08-21

pyrazines and Triple Negative Breast Neoplasms

pyrazines has been researched along with Triple Negative Breast Neoplasms in 10 studies

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	6 (60.00)	24.3611
2020's	4 (40.00)	2.80

Authors

Authors	Studies
Awasthi, S; Gmeiner, WH; Jonnalagadda, S; Lingareddy, J; Mani, C; Palle, K	1
Gatti-Mays, ME; Green, JE; Karzai, FH; Lee, JM; Lee, MJ; Lipkowitz, S; McCoy, A; Nair, J; Soltani, SN; Trepel, JB; Yuno, A; Zimmer, A	1
Chen, L; Craven, R; Hamad, N; He, S; Huang, JA; Li, J; Liu, C; Liu, Z; Lu, X; Napier, D; Pan, Y; Qian, H; Shi, J; Thibault, O; Wang, C; Wei, D; Wei, X; Wu, Y; Xu, B; Xu, L; Yang, H; Yang, XH; Zhang, Y; Zheng, X; Zhou, BP	1
Amant, F; Annibali, D; Baietti, MF; Floris, G; Impens, F; Marangoni, E; Marinelli, O; Moens, S; Neven, P; Sablina, AA; Van Haver, D; Zhao, P	1
Chen, S; Huang, J; Huang, Q; Li, Y; Luo, Y; Wang, C; Wu, W; Yu, L; Zha, D; Zhang, C; Zhang, J; Zhou, W	1
Alcoser, SY; Aziz, A; Borgel, S; Bottaro, DP; Colantonio, S; Dieckman, L; Doroshow, JH; Hiltke, T; Hollingshead, MG; Kaczmarczyk, J; Kinders, RJ; Lee, YH; Navas, T; Parchment, RE; Pfister, TD; Saul, RG; Takebe, N; Tomaszewski, JE; Whiteley, G	1
Boughey, JC; Goetz, MP; Harmsen, WS; Kahila, MM; Kalari, KR; Lou, Z; Mutter, RW; Sarkaria, JN; Tu, X; Wang, L; Yu, J; Yuan, J; Zhou, Q	1
Benes, CH; Borgmann, K; Dinkelborg, PH; Gheorghiu, L; Gurski, JM; Hong, TS; Jimenez, RB; Juric, D; Wang, M; Willers, H	1
Chen, CH; Chen, JY; Chen, WS; Chen, YJ; Chien, PH; Hsia, TC; Huang, WC; Liu, SH; Shih, CY; Tu, CY; Wei, YL; Yeh, MH; Yu, MC; Yu, YL	1
Chen, K; Gaur, S; Hu, S; Liu, YR; Pan, SL; Tzeng, HE; Wang, Y; Yang, L; Yen, Y	1

Trials

1 trial(s) available for pyrazines and Triple Negative Breast Neoplasms

Article	Year
A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer. The oncologist, 2020, Volume: 25, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Pilot Projects; Pyrazines; Pyrazoles; Triple Negative Breast Neoplasms	2020

Other Studies

9 other study(ies) available for pyrazines and Triple Negative Breast Neoplasms

Article	Year
Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells. Breast cancer research : BCR, 2019, 09-06, Volume: 21, Issue:1 Topics: Antineoplastic Agents; Biomarkers, Tumor; BRCA1 Protein; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Homologous Recombination; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyrazines; Pyrazoles; Rad51 Recombinase; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2019
BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways. Cellular oncology (Dordrecht), 2020, Volume: 43, Issue:6 Topics: Azepines; Bcl-2-Like Protein 11; Benzamides; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Cell Survival; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Integrins; Proto-Oncogene Proteins c-myc; Pyrazines; RNA, Messenger; Signal Transduction; Sulfonamides; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms	2020
The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers. Scientific reports, 2021, 02-04, Volume: 11, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Protein-Tyrosine Kinases; Proteome; Pyrazines; Pyrazoles; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2021
Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents. Bioorganic & medicinal chemistry letters, 2021, 09-01, Volume: 47 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chalcone; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Pyrazines; Structure-Activity Relationship; Triple Negative Breast Neoplasms	2021
Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. PloS one, 2018, Volume: 13, Issue:6 Topics: AC133 Antigen; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Gene Knock-In Techniques; Hepatocyte Growth Factor; Humans; Indicators and Reagents; Lung Neoplasms; Mice, Transgenic; Neoplastic Stem Cells; Phenotype; Pyrazines; Sulfonamides; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays	2018
ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. Molecular cancer therapeutics, 2018, Volume: 17, Issue:11 Topics: Animals; Ataxia Telangiectasia Mutated Proteins; cdc25 Phosphatases; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; DNA Breaks, Double-Stranded; Drug Resistance, Neoplasm; Female; Homologous Recombination; Humans; Isoxazoles; Mice, Inbred NOD; Mice, SCID; Phosphorylation; Proteolysis; Pyrazines; Radiation-Sensitizing Agents; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2018
A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types. Breast cancer research and treatment, 2019, Volume: 174, Issue:3 Topics: Adenocarcinoma of Lung; Biopsy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; DNA Breaks, Double-Stranded; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Leukemic; Humans; Lung Neoplasms; MCF-7 Cells; Mutation; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Small Molecule Libraries; Triple Negative Breast Neoplasms	2019
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors. Breast cancer research : BCR, 2013, Nov-12, Volume: 15, Issue:6 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; I-kappa B Kinase; Lapatinib; Mice, SCID; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2013
The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor. Oncotarget, 2015, May-10, Volume: 6, Issue:13 Topics: Animals; Apoptosis; beta Catenin; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; Humans; Indazoles; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Wnt Proteins; Xenograft Model Antitumor Assays	2015